Usona vs. COMPASS — Two Very Different Roads to FDA Approval
22 replies · News & Policy
There are two psilocybin programs with significant FDA trial data: COMPASS Pathways (COMP360, synthetic, UK-based biotech) and Usona Institute (PSIL201, natural-source, nonprofit). They're pursuing FDA approval through very different structures with very different implications for access and cost. Can someone explain the differences? I keep seeing them conflated.
COMPASS Pathways is a for-profit UK biotech. Their goal is FDA approval of COMP360 (synthetic psilocybin) as a Schedule II pharmaceutical administered in licensed clinical settings. If approved, COMPASS would hold IP and control pricing — initial estimates suggest $10,000-20,000+ per treatment course, similar to esketamine (Spravato). Insurance coverage would likely follow eventually, but access at launch would be restricted to those who can afford it.
Usona Institute is a nonprofit. Their explicit mission is ensuring psilocybin therapy is accessible, not profitable. PSIL201 is natural-source psilocybin derived from mushroom extraction rather than total synthesis. Usona has publicly stated they will not price-gouge and plan to license broadly. Their Phase 2 MDD data is also strong — they published a positive RCT in JAMA Psychiatry. Phase 3 is ongoing.
The structural difference matters enormously: COMPASS succeeding means psilocybin therapy exists but is expensive. Usona succeeding means psilocybin therapy exists with more emphasis on broad access. In practice, both getting FDA approval in the 2027-2029 window would be the best outcome — competition between a for-profit and nonprofit creates pricing pressure.
19 more replies — forum posting coming soon.